Deletion Mutants of VPg Reveal New Cytopathology Determinants in a Picornavirus

Armando Arias1*, Celia Perales1,2, Cristina Escarmís1, Esteban Domingo1,2

1 Departamento de Virologı´ a y Microbiologı´ a, Centro de Biologı´ a Molecular “Severo Ochoa” (CSIC-UAM), Consejo Superior de Investigaciones Cientı´ ficas (CSIC), Campus de Cantoblanco, Madrid, Spain, 2 Centro de Investigacion Biomédica en Red de Enfermedades Hepa´ ticas y Digestivas (CIBERehd), Barcelona, Spain

Abstract

Background: Success of a viral infection requires that each infected cell delivers a sufficient number of infectious particles to allow new rounds of infection. In picornaviruses, viral replication is initiated by the viral polymerase and a viral-coded protein, termed VPg, that primes RNA synthesis. Foot-and-mouth disease virus (FMDV) is exceptional among picornaviruses in that its genome encodes 3 copies of VPg. Why FMDV encodes three VPgs is unknown.

Methodology and Principal Findings: We have constructed four mutant FMDVs that encode only one VPg: either VPg1, VPg3, or two chimeric versions containing part of VPg1 and VPg3. All mutants, except that encoding only VPg1, were replication-competent. Unexpectedly, despite being replication-competent, the mutants did not form plaques on BHK-21 cell monolayers. The one-VPg mutant FMDVs released lower amounts of encapsidated viral RNA to the extracellular environment than wild type FMDV, suggesting that deficient plaque formation was associated with insufficient release of infectious progeny. Mutant FMDVs subjected to serial passages in BHK-21 cells regained plaque-forming capacity without modification of the number of copies of VPg. Substitutions in non-structural proteins 2C, 3A and VPg were associated with restoration of plaque formation. Specifically, replacement R55W in 2C was repeatedly found in several mutant viruses that had regained competence in plaque development. The effect of R55W in 2C was to mediate an increase in the extracellular viral RNA release without a detectable increase of total viral RNA that correlated with an enhanced capacity to alter and detach BHK-21 cells from the monolayer, the first stage of cell killing.

Conclusions: The results link the VPg copies in the FMDV genome with the cytopathology capacity of the virus, and have unveiled yet another function of 2C: modulation of picornavirus cell-to-cell transmission. Implications for picornaviruses pathogenesis are discussed.

Introduction

Contrary to initiation of cellular DNA replication which is primed by RNA molecules synthesised by cellular primases [1], viruses use a wide variety of molecular mechanisms to initiate genome replication, that include de novo initiation, priming by proteins or by self generated 3’–ends of templates, and ‘cap–snatching’, among other mechanisms [2]. Protein–primed initiation of genome replication is used by several DNA and RNA viruses and some linear plasmids [3–5]. Picornaviridae is a family of positive strand RNA viruses that use as protein–primer a single viral polyprotein which is translated from a single ORF. Picornaviral proteins are generated by proteolytic processing of the genomic RNA encapsidated into viral particles. Picornaviruses encode only one copy of VPg, except foot-and-mouth disease virus (FMDV) that expresses three similar but non–identical copies of VPg (VPg1–3 or 3B1–3) [8] (Figure 1). Each of the three VPgs are found covalently bound to genomic viral RNA [9] and they can be uridylylated in vitro by the viral polymerase, with VPg3>VPg2>VPg1 as the order of substrate efficiency [10]. The biological meaning of this unique in–tandem repetition in an RNA virus is not well understood [11,12]. Molecular poliovirus clones constructed to express two VPgs delete one of the copies, and the polypeptide harboring two VPgs underwent aberrant processing [13,14]. FMDV encoding only VPg3 is infectious in cell culture, showing that one copy of VPg may be sufficient to complete the virus replication cycle [12]. The virus expressing only VPg3 was infectious for hamster and bovine fibroblasts (BHK and FBK cells), but not swine fibroblasts (FPK cells), and was attenuated for swine [12]. FMDVs encoding VPg1 and VPg2, but lacking VPg3 were not viable, suggesting that the presence of VPg3 was essential for FMDV viability [11]. The authors proposed that this loss of viability could be due to a defect in the proteolytic processing of the viral polyprotein precursor lacking VPg3 [11]. Picornaviral proteins are generated by proteolytic processing of a single viral polyprotein which is translated from a single ORF.
FMDV clones were constructed either to express VPg1 (V1), VPg3 (V3), or a chimeric VPg containing the first 15 residues from VPg1 and the last 9 residues from VPg3 (V15–9). The starting pMT28 plasmid and procedures for the construction are detailed in Materials and Methods.

**Results**

FMDVs with only one VPg copy are replication-competent viruses

Previous studies showed that FMDV encoding VPg3, as the only copy of VPg (but not FMDV encoding only VPg1 and VPg2), is infectious in cell culture [11,12]. It was not clear whether lethality was due to absence of VPg3, or to absence of the protolytic cleavage site between VPg3 and 3C [11]. To address whether VPg3 is essential for FMDV replication, and to investigate the function of repeated VPg genes in Aphthoviruses, we have designed FMDVs with only VPg1 (termed V1), only VPg2 (termed V2), and chimeric viruses containing most of VPg2 but a short C-terminal portion of VPg3 that restores the cleavage site between VPg2 and 3C. The chimeric-VPg viruses have been termed V19–4 (first 19 residues from VPg2 and last 4 residues from VPg3) and V15–9 (first 15 residues of VPg2 and last 9 residues from VPg3) (Figure 1). All mutant viruses, except V1, were competent in replication when the corresponding RNAs were transfected into BHK-21 cells, as evidenced by quantification of virus-specific RNA and proteins (Figure 2). The results show that a complete sequence of VPg is not essential for viral replication, but VPg-containing mutants require additional residues from VPg2 in their C-terminus for replication.

Viral proteins, measured by metabolic labelling and Western blot analysis, were detected with all mutants except V1 (Figure 2A–C). As expected, all mutant constructs that expressed replication-competent RNAs gave rise to a P3 polyprotein precursor that displayed higher mobility than wild type (WT) P3, due to the deletion of two VPg copies (Figure 2B and 2C). The pattern of processed P3 proteins in the expression products of V19–4 and V15–9 supports an efficient processing of the precursor 3BC into 3B and 3C, in agreement with the introduction of a functional 3C cleavage site in the mutants (Figure 2C). Quantification of total (intracellular and extracellular) viral RNA collected from cell cultures transfected with mutant FMDVs yielded $10^5$–$10^7$ viral RNA molecules/cell (vRNA/cell) for mutants V3, V15–9 and V19–4, a value which is 10–100-fold lower than that obtained for FMDV WT (Figure 2D). Mutant V1 showed a viral RNA level that was 10,000-fold lower than WT (<10^3 viral RNA molecules/cell), suggesting that replication of V1 is either drastically reduced or abrogated (Figure 2). It cannot be excluded that the low viral RNA level detected after transfection with V1 RNA could be a remnant of the RNA used in the transfection (10^3 viral RNA molecules/cell), and it confirms the positive replication of the
other mutants. In summary, there is no requirement of a specific VPg sequence for FMDV viability since the three different VPg versions confer replication-competence to a similar extent. However, the presence of a 3C protease cleavage site between VPg and 3C seems to be needed for viral RNA synthesis.

FMDVs expressing a single VPg lack plaque-forming capacity

Samples from the cell culture supernatants of BHK-21 cells transfected with V1, V3 or V19-4 RNAs did not include detectable viral infectivity in a standard FMDV plaque assay (<5 PFU/ml), with plaques visualised at 48 hours post-plating (FMDV WT plaques are readily detectable at 24 hours post-plating) (Figure 2E). Samples from transfection with V15-9 presented detectable infectivity \([8(\pm3)\times10^5\text{ PFU/ml}]\), albeit 1,000- to 10,000-fold lower than WT \([3(\pm2)\times10^6\text{ PFU/ml}]\). The absence of plaque development with V3 or V19-4 contrasted with the large amounts of total viral genomic RNA detected in the same cell cultures (Fig 2D), and with the observed intracellular levels of viral proteins (Figure 2A-C). The specific infectivity (SI, ratio between viral titre and the number of viral RNA molecules) of viruses expressing only one VPg is lower than 1:20,000,000, which is at least 500-fold lower than that of...
FMDV WT (1:40,000). For standard FMDV C–S8c1, the ratio of infectious particles to total number of physical particles was previously estimated in 1:7,000 to 1:10,000 [38], and the ratio decreases when FMDV is subjected to mutagenesis [39]. Thus, viruses expressing a single VPg are competent for viral protein synthesis and RNA synthesis, but defective in plaque development (Figure 2).

The specific infectivity of mutant FMDVs is gradually regained upon passage in BHK–21 cells

To investigate whether the capacity of FMDV mutants V1, V3, V19–4 and V15–9 to form plaques could be restored upon further virus replication, the virus present in supernatants collected from cell cultures initially transfected with 100 ng (series A) or 500 ng (series B) of V1, V3, V19–4 and V15–9 RNA was serially passaged in BHK–21 cells. At the first passage (p1), cytopathology was complete in cells infected with V3 and V15–9, but affected only 10% of the cells infected with V19–4, at 70–90 hours post-infection (hpi), and no cytopathology was observed with the supernatants that should contain the progeny of V1 RNA. For FMDV WT, complete cytopathology was observed at 30 hpi, in agreement with previous observations [40]. Infectivity was detected for all viruses (except for V1) at p1, although mutant viruses yielded lower titres and SI values than WT. Successive passages led gradually to a more extensive cytopathology at shorter times pi, and to increases in viral titre and SI for all mutants tested, except for V1 (Figure 3). Plaque development by FMDV on BHK–21 cell monolayers is a reflection of cell detachment as a manifestation of virus infection. Therefore, in the assays described here, cytopathology refers as cell rounding and detachment as a result of the cellular modifications previously described for BHK–21 cells lytically infected by FMDV [36,37].

Multiple genomic sites are involved in recovery of the plaque–forming phenotype

To investigate whether plaque–forming capacity was regained via adaptive mutations in the viral genome, the entire genomic consensus sequence [except the genomic 5′ and 3′ termini, and the nucleotides upstream and downstream from of the polyC tract] of six mutant populations at passage 2 (series A and B) for mutants V3, V19–4 and V15–9 was determined. Although no mutation was repeated in all populations, amino acid substitution R55W in non–structural protein 2C was present in populations V3B, V19–4B and V15–9B (Table 1). This result suggested that substitution R55W in 2C could be involved in restoring the plaque–forming phenotype in these three populations. The only substitution that affected VPg was E8K found in population V19–4A (Table 1).

Recovery of the plaque–forming phenotype was not associated with any dominant mutation in two out of six populations at passage 2 (V3A and V15–9A). To determine whether the mutant spectrum of V3A included genomes with the same mutations found in the other lineages, the P2–P3–coding region of virus isolated from 3 individual plaques derived from population V3A at passage 1 was sequenced. Each clone included non–synonymous mutations in 2C and/or 3A, and two clones presented replacement R55W in 2C (Table 1). The results suggest that plaque–development in the VPg mutants can be attained by any of a number of substitutions in non–structural proteins 2C, 3A and/or VPg. Since R55W in 2C was found in several clones and populations, its effect on FMDV progeny production and cytopathology was further investigated.

2C substitution R55W increases the specific infectivity of FMDV expressing a single VPg

To determine whether substitution R55W in 2C could restore the plaque–forming capacity of FMDV mutants with alterations in 2C (FMDV mutants V3, V19–4 and V15–9, Figure 1), the corresponding mutation was introduced in each of the mutant constructs that express one VPg. All mutants regained the plaque–forming phenotype (Figure 4A) that resulted in 17– to 190–fold increase of specific infectivity of each viral RNA transcript (Figure 4B). To minimize the emergence of adaptive mutations during plaque development, serially diluted viral RNA transcripts were transfectioned into cells, and plaque development was permitted under semisolid agar medium. Plaques were formed by all mutants expressing only one VPg and 2C with R55W, and they were visible at 3 days post–transfection. No plaques were formed by their RNA counterparts expressing wild type 2C, under the same conditions. By 2 days post–transfection, plaques were already detected for V15–9 and V3 with R55W in 2C, but not for V19–4 with R55W in 2C (Figure 4). Thus, 2C substitution R55W is sufficient to restore the plaque–forming capacity of the mutants tested that express one VPg.

R55W in 2C increases cytopathic effect and results in enhanced viral release from cells

To investigate the effect of R55W 2C in FMDV replication, viral RNA and viral protein levels of FMDVs expressing 2C with either R55 (wild type) or W55 (adaptive substitution) were quantified at different times post–electroporation. Positive RNA replication was observed for all mutants (V3, V19–4 and V15–9 with or without R55W in 2C) with RNA levels reaching an amount at least 10–fold higher than levels quantified at the time of electroporation (Figure 5A). To ascertain the presence of newly synthesised viral RNA molecules, the background RNA value scored at the time of the electroporation was subtracted from each of the values obtained at different times after electroporation. The results (Figure 5A) indicate that the presence of R55W in 2C of the FMDV mutants increased the amount of extracellular viral RNA without any significant increase in the total viral RNA levels (intracellular plus extracellular). The ratio of extracellular to total viral RNA molecules was estimated to be in the range of 0.1 to 0.4 for mutants encoding R55W in 2C, and 0.03 to 0.04 for mutants encoding wild type 2C (Figure 5B).

The selective increase of extracellular RNA suggests increased exit of viral particles. This implies that higher extracellular concentrations of capsid proteins should be found for mutants expressing 2C with R55W than for the same mutants expressing wild type 2C. This was confirmed by determining extracellular levels of capsid proteins VP1 and VP3. First, the synthesis of capsid proteins VP1 and VP3 was ascertained in the electroporated cells by pulse-labeling with [35S] Met-Cys at 3 h to 4 h post–electroporation. The result (Figure 5C) revealed the presence of VP1 and VP3 in the extracellular RNA and viral protein levels of FMDVs expressing 2C with R55W in 2C could be involved in restoring the plaque–forming phenotype in these three populations. The only substitution that affected VPg was E8K found in population V19–4A (Table 1).

Recovery of the plaque–forming phenotype was not associated with any dominant mutation in two out of six populations at passage 2 (V3A and V15–9A). To determine whether the mutant spectrum of V3A included genomes with the same mutations found in the other lineages, the P2–P3–coding region of virus isolated from 3 individual plaques derived from population V3A at passage 1 was sequenced. Each clone included non–synonymous mutations in 2C and/or 3A, and two clones presented replacement R55W in 2C (Table 1). The results suggest that plaque–development in the VPg mutants can be attained by any of a number of substitutions in non–structural proteins 2C, 3A and/or VPg. Since R55W in 2C was found in several clones and populations, its effect on FMDV progeny production and cytopathology was further investigated.
produced in sufficient amounts. However, the cell killing assay was applied to wild type FMDV expressing either wild type 2C or 2C with R55W and the results showed 8- to 20-fold increases of cytopathology associated with substitution R55W in 2C (Figure 6A).

In other assays, the number of detached cells versus the total number of cells was measured following electroporation with V3, V19–4 and V15–9 RNAs, expressing either 2C wild type or 2C with R55W, as a means of circumventing the requirement of infectious virus particles. The results (Figure 6B) show that the proportion of cells detached was 62±3%, 79±6% and 72±10% in transfections with mutants V19–4, V15–9 and V3 encoding R55W in 2C, respectively, while these values were 26±11%, 45±10% and 38±3% in transfections with the same mutants encoding the wild type 2C, and this difference was statistically significant (p = 0.0002; Student’s t–Test). To prevent multiple–step growth conditions that may have affected the interpretation of results, the experiment was carried out by using 5 μg of viral RNA for 10^6 BHK-21 cells, a sufficient amount to ensure that more than 90% of the cells were efficiently transfected Therefore, substitution R55W in 2C favors both release of viral particles and cytopathology.

**Figure 3. Recovery of infectivity of FMDV mutants expressing one VPg, upon serial passages in BHK–21 cells.** 2×10^6 BHK-21 cells were transfected with 100 ng (series A) (panels A, B, C) or 500 ng (series B) (panels D, E, F) of the FMDV transcripts indicated in the boxes. Cells and cell culture supernatants were collected at 72 h post-transfection (passage 0). Successive passages were carried out by infecting BHK–21 cells with the viruses from the cell culture supernatant of the previous passage, and samples were collected when cytopathology was complete (generally 20 to 30 hours pi). A, D, Viral infectivity as a function of passage number; plaque development was for 48 hours. B, E, Number of genomic RNA molecules in the cell culture supernatants. C, F, Specific infectivity calculated as the number of PFU per 10^10 viral RNA genomes, from the data given in A, B and D, E. Measurements were carried out in triplicate and standard deviations are given. Procedures for titration of infectivity and determination of viral RNA levels are described in Materials and Methods.

doi:10.1371/journal.pone.0010735.g003
Further analyses with FMDV mutants expressing one VPg

The major defect of FMDV mutants V19-4, V15-9 and V3 that express a single VPg is the absence of cytopathology associated with limited release from cells with no impairment of intracellular viral RNA levels. To test whether other viral functions might also be affected in these mutants, cell entry and intracellular viral protein synthesis were also examined.

To determine whether mutants expressing a single VPg could also manifest a defect in cell entry, the capacity of mutants V19-4 and V3 expressing either wild type 2C or 2C with R55W to enter cells was determined. For this purpose, viral samples were collected from cell cultures at 4 hours post-transfection by freeze-thawing the cells to liberate virus, and then applied to a BHK-21 cell monolayer. The input FMDV RNA applied to the monolayer and the FMDV RNA that entered BHK-21 cells was determined. For 5 independent biological clones isolated from population V3A at passage 1. The origin of each population is described in the text and in Figure 3.

To compare intracellular protein synthesis directed by the mutant FMDVs, proteins were metabolically labeled between 3 and 4 hours post-electroporation. BHK-21 cells infected with mutants V3, V19-4 and V15-9 encoding R55W in 2C presented modestly higher levels of viral proteins than the same mutants expressing a wild type 2C (Figure 4). Therefore, a limitation in protein synthesis cannot be related to a defect in viral release from cells.

Substitution E8K in VPg contributes also to increased viral release in mutant viruses expressing one VPg

Mutant V19-4 (R55W) showed a delayed plaque formation relative to other mutants encoding R55W in 2C (Figure 4). To investigate whether additional replacements could accelerate plaque formation in this virus, populations V19-4A and V19-4B at passage 2 (depicted in Table 1 and Figure 3) were subjected to 25 additional passages in BHK-21 cells. E8K in VPg1 was the only replacement repeatedly found in the two V19-4 lineages at passage 27 (Table 2). Interestingly, R55W in 2C became dominant during the 25 additional passages in lineage V19-4A in which R55W was not present at passage 2 (compare Tables 1 and 2). However, in lineage V19-4B, W55 was dominant at passage 2 but had reverted to R55 by passage 27. This reversion was accompanied by dominance of substitution I85V in 2C (Table 2).

Other amino acid replacements were identified in other viral proteins of passage series A and B (Table 2).

Since R55W in 2C and E8K in VPg1 were found together in V19-4A at passage 27, the effect of both substitutions together in the same genome in the sequence context of V19-4 was investigated. The double mutation restored plaque-forming capacity, with minute plaques detected at 48 h post-transfection (Figure 8A). The specific infectivity of V19-4 increased 10- to 100-fold as a result of expressing 2C with R55W alone or together with VPg with E8K (Figure 8B). The extracellular viral RNA was 5- to 11-fold higher for V19-4 (R55W,E8K) than for wild type FMDV (Figure 8C). The specific infectivity of V19-4 (R55W,E8K) was also 5- to 11-fold higher than for wild type FMDV (Figure 8D). Protein levels were 1- to 4-fold relative to V19-4 or V19-4 (R55W) (Figure 8C), and this difference was statistically significant (P<0.0001; unpaired t-Test). Metabolic labelling of cells transfected with V19-4 (R55W,E8K) revealed that viral protein synthesis was increased 2.2- to 4.4-fold relative to V19-4 or V19-4 (R55W). Protein levels were 1.6-fold higher for V19-4 (R53W,E8K) than for wild type FMDV (Figure 8C). These measurements suggest that viral release into the extracellular medium was enhanced by substitution E8K in VPg.

In summary, FMDV expressing only one VPg is defective in cell-to-cell propagation and this defect is reverted by an increase in viral release, concomitantly with restoration of cytopathology, mediated by substitutions in 2C, VPg or other non-structural proteins.

### Table 1. Substitutions found in FMDV mutants that encode one VPg, upon passage in BHK-21 cells.

| Genomic region | Mutation | Amino acid substitution | Presence in biological clones from V3A at passage 1 | Presence in uncloned population at passage 2 |
|---------------|----------|-------------------------|---------------------------------------------------|-------------------------------------------|
| L             | C4778U   | T135I                   | —                                                  | V19-4A                                   |
| 2C            | C4507U   | R55W                    | c1, c4                                             | V19-4B; V15–9B; V3B                       |
|               | C4778U   | T135I                   | c2                                                 | —                                        |
|               | A4988G   | K215R                   | —                                                  | V15–9B                                   |
| J3            | A5422C   | I42L                    | c3, c5                                             | —                                        |
| VPg-coding region | G5779A | E8K                     | —                                                  | V19-4A                                   |
| 3C            | C6060U   | —                       | —                                                  | —                                        |
| 3D<sup>nu</sup> | A7487G | E293G                   | c1                                                 | —                                        |

<sup>a</sup>The consensus sequence of the entire viral genome was determined for FMDV populations V3, V19-4 and V15-9 (series A and B) after 2 passages in cell culture (experiment described in Figure 3). The sequence of viral genomic regions 2C, 3A, 3B (VPg), 3C and 3D (residues from genomic position 4200 to 8115) was determined for 5 independent biological clones isolated from population V3A at passage 1. The origin of each population is described in the text and in Figure 3.

<sup>b</sup>FMDV genomic region analysed [15].

<sup>c</sup>Mutations and deduced amino acid substitutions are relative to the sequence of the parental clone FMDV WT (pMT28, described in Materials and Methods); residue numbering is according to [49]. Amino acid residues (single-letter code) are numbered individually for each protein from the N- to the C-terminus. Procedures for nucleotide sequencing and identification of FMDV genomic regions are described in Materials and Methods.

<sup>d</sup>Populations and biological clones in which the substitutions indicated in ‘ were found.

Table 1. Substitutions found in FMDV mutants that encode one VPg, upon passage in BHK-21 cells.
Discussion

Two features of RNA virus evolution are relevant to the interpretation of the results with VPg mutants of FMDV reported here. One is the multifunctional nature of many (probably most) proteins encoded in the compact RNA genomes, particularly in the case of picornaviruses in which several intermediates obtained in the processing of the polyprotein play essential roles in the virus life cycle. In the present study, multifunctionality was manifested by the participation of 2C in the compensation of a defect in the release from cells of FMDVs that do not express the 3 VPg versions encoded by wild type FMDV [42]. Such compensation suggests a role of 2C in functions additional to those described for this non–structural protein [20,21,24-27,43]. The second relevant feature of RNA virus evolution is the functional connection among different genomic regions, in this case between VPg and other non–structural proteins, regarding expression of phenotypic traits [44].

The results reported here indicate that the replication-competent FMDV mutants that expressed a single VPg were deficient in plaque formation, a defect related to the inability to cause cytopathology. Cell rounding and detachment from the monolayer precede cell death. The mechanism (apoptosis, necrosis, autophagy) by which FMDV kills BHK-21 cells in cell culture has not been elucidated [45], and our attempts to confirm or exclude apoptosis of BHK-21 cells following infection by FMDV have not been conclusive (C. Perales, unpublished observations). We have observed that the first step towards cell death --as measured either by trypan blue staining or by fluorescence-activated cell sorting (FACS) using propidium iodide that gave equivalent quantifications [46]-- is cell rounding and detachment of the monolayer. The capacity to produce cytopathology was rapidly restored upon passage of the mutant viruses in BHK-21 cells, that acquired amino acid substitutions in non–structural proteins, including R55W in 2C. The results suggest that substitution R55W in 2C permitted FMDVs that expressed a single VPg to attain a critical number of viral particles released from cells, that are associated with cytopathology. An approximate value of 5 infectious particles released per BHK–21 cell was estimated as the minimum number needed to develop a plaque under our experimental conditions (Table 5). This is the number of particles released per cell estimated for mutant V19–4 (R55W)

![Figure 4. Restoration of the plaque–forming phenotype in FMDV mutants by replacement R55W in 2C. RNA transcripts (10 ng for 48 hours of plaque development and 1 ng for 72 hours plaque development) were transfected into 2 × 10^6 BHK–21 cells. At 2 hours post–transfection cell culture supernatants were removed and the cells were overlaid with semisolid agar medium. A. Plaque assay of directly transfected FMDV RNA transcripts encoding either wild type 2C (left) or 2C with substitution R55W (right). For mutants V15–9, V19–4 and V3, plaques were detected when 2C included substitution R55W. WT(0.2x) represents transfections with a fifth of the amount used for the rest of the assays. Plaques for mutant V19–4 (R55W) were not detected at 48 hours post–transfection. V3 formed some plaques at 72 hours post–transfection but not at 48 hours post–transfection. The number of plaques formed by V3 was 18–fold lower than the number formed by V3 encoding R55W in 2C. B. Specific infectivity measured as the ratio of the number of PFU at 72 hours post–transfection to the amount of viral transcript used in the electroporation. Assays were carried out in triplicate, and standard deviations are given. Procedures for plaque assays of transfected cells are described in Materials and Methods. doi:10.1371/journal.pone.0010735.g004](image)
Figure 5. Effect of replacement R55W in 2C in the release of FMDV RNA from cells. $10^6$ BHK–21 cells were electroporated with 8 μg of either V19–4, V3, V15–9 or WT RNAs. Then the cells were transferred to M24–wells. A, Total viral RNA (intracellular and extracellular) and extracellular RNA were quantified by real–time RT–PCR, at the indicated hours post-electroporation (hpe). The amount of FMDV RNA was normalised to the number of cells seeded in the corresponding wells. The viral RNA (total and extracellular) measured just after electroporation was subtracted from each corresponding value. Note that RNAs encoding R55W in 2C are significantly more efficient in promoting release of viral RNA from cells at 6 hours post–transfection than those expressing wild type 2C ($p<0.05$; paired $t$–Test). B, Ratio of FMDV RNA released from the cells (ratio of extracellular viral RNA to total RNA) at 6 hours post–electroporation, determined from the data shown in A. Assays in A and B were carried out in triplicate and standard deviations are given. C, Detection of capsid proteins VP3 and VP1 in mutant FMDVs expressing 2C with or without replacement R55W. $10^6$ BHK–21 cells were electroporated with 8 μg of viral RNA. At 3 hours post–electroporation, supernatants were removed and DMEM without Met and Cys, but supplemented with [35S] Met–Cys, was added. At 4 hours post–electroporation, supernatants were removed and cells were collected to analyse the synthesis of the viral capsid proteins VP3 and VP1. D, Extracellular samples of cell cultures electroporated with the
indicated mutant FMDV RNAs, labelled as described in C, were collected at 2 (0-2 hours) and 20 (2-24 hours) hours post–labelling (6 and 24 hours post–electroporation). Samples were analysed by SDS–PAGE (15% acrylamide). VP3 and VP1 were detected at early time (4 to 6 hours post–transfection) in the supernatant of cells transfected with 8 μg of V15–9 or V3 encoding 2C with R55W, but not with the same amount of RNA from constructs encoding wild type 2C. At later times (6 to 24 hours post–transfection), VP3 and VP1 were detected in the supernatant of cells transfected with any of the constructs tested. Procedures are further detailed in Materials and Methods.

Figure 6. Effect of replacement R55W in 2C on FMDV cytopathology. A, BHK–21 cell-killing assay [40] carried out with either FMDV WT (expressing three VPgs) with the standard 2C (abbreviated as WT) or FMDV WT with substitution R55W in 2C (abbreviated as WT R55W). Serial dilutions of either FMDV WT or FMDV R55W were applied to wells containing 10^4 BHK–21 cells each. The plot depicts the minimum MOI (PFU/cell) (expressing three VPgs) with the standard 2C (abbreviated as WT) or FMDV WT with substitution R55W in 2C (abbreviated as WT R55W). Serial dilutions of either FMDV WT or FMDV R55W were applied to wells containing 10^4 BHK–21 cells each. The plot depicts the minimum MOI (PFU/cell) required to cause complete cytopathology (detachment of all cells from the monolayer) at the indicated hours post-infection, as previously described [40]. Results are the average of four independent determinations. Note that the presence of R55W in 2C decreases the MOI needed to cause complete cytopathology for a given time. B, Quantification of cytopathology (percentage of cells detached from the monolayer) in cells with RNA from wild type (WT) or mutants V19–4, V15–9 or V3 expressing either wild type 2C or 2C with substitution R55W. At 8 h post-electroporation the total number of cells and the number of detached cells were counted; a correction was introduced to account for the number of cells that were detached due to the electroporation by parallel measurements with mock-electroporated cells (around 50% of cell detachment). Results are the average of three determinations.

doi:10.1371/journal.pone.0010735.g006

which is near the threshold of not being competent in plaque development; the plaques formed by this virus were visible only at late times post–transfection. The functional basis for this critical number is not known.

Residue 55 of 2C [and also residue 85, substituted in the R55W revertant of V19–4B (see Results)] is located in the region comprised between the expected membrane-binding domain and the predicted NTPase/helicase domain A, and it is a variable residue when 2Cs of different picornaviruses are aligned. Positions 55 and 85 have not been identified as related to resistance to guanidine in FMDV [47,48] and therefore, from the data presently available no connection between 2C positions 55 and 85 and FMDV replication is apparent. It cannot be excluded that the established role of 2C in cellular membrane rearrangements during picornaviral infection [27–31] might be connected with its effect in virus release and cytopathology.

With the assumption that cytopathology by FMDV precedes cell death, several determinants of BHK–21 cell killing were previously mapped in the IRES, the viral capsid, and non–structural proteins of the virus [40,49,50], and it is a variable residue when 2Cs of different picornaviruses are aligned. Positions 55 and 85 have not been identified as related to resistance to guanidine in FMDV [47,48] and therefore, from the data presently available no connection between 2C positions 55 and 85 and FMDV replication is apparent. It cannot be excluded that the established role of 2C in cellular membrane rearrangements during picornaviral infection [27–31] might be connected with its effect in virus release and cytopathology.

The molecular basis of the increased cytopathology observed for mutants that encode 2C with substitution R55W remains unknown.

Since a modest increase in viral protein synthesis in these mutants is observed despite no increase in viral RNA levels, an appealing hypothesis is that 2C has some involved in translation, and that R55W might enhance protein synthesis modestly but to a level sufficient to contribute to enhanced cytopathology. The effect of substitution R55W could be exerted during polyprotein processing, by rendering 2C more sensitive to polyprotein cleavage mediated by 3C. Distance effects of amino acid substitutions on FMDV polyprotein processing have been previously documented [51]. Other interpretations are possible. For example, since 2C is a multifunctional protein [20–31], substitution R55W may alter virus–host interactions that lead to enhanced cytopathology, being the slight increase of protein synthesis an indirect consequence of alterations in other viral functions.

Substitution E8K was also found associated with the one-VPg mutants that regained capacity to cause cytopathology. The crystal structure of the complex between 3D and VPg predicts that E8 participates directly in the interaction with the viral polymerase. Although E8 is far from the UMP residue bound to VPg (covalent bond Tyr3-UMP), substitution E8K has been shown to affect drastically the uridylylation of VPg by 3D [52]. The molecular basis of the phenotypic effect of VPg replacement E8K remains unknown.

Despite the fact that the behavior of the one-VPg FMDV mutants studied here suggests a functional connection between 2C and VPg in FMDV, to our knowledge a direct interaction between the two proteins has not been documented in picornaviruses. Nevertheless, PV 2C interacts with the VPg precursor 3AB (3B) [33]. In an FMDV–infected cell, a possible 3AB–2C interaction could be mediated by more than one VPg copy, and the alteration
Figure 7. Viral proteins expressed by mutant FMDVs encoding either wild type 2C or 2C with R55W. A, Electrophoretic analysis of proteins labelled with [35S] Met–Cys. 10^6 BHK–21 cells were electroporated with 2 or 8 μg of the indicated viral RNAs; At 3 hours post-electroporation, supernatants were removed and DMEM without Met and Cys but supplemented with [35S] Met–Cys was added. One hour later, cell culture supernatants were removed and cells were collected in loading buffer, proteins were resolved in SDS–PAGE (15% acrylamide), and the gel was dried and exposed. Viral proteins, identified by their reactivity with specific MAbs [62], are indicated with an asterisk. B, Close-up view of the bands in A corresponding to 3CD and 3BCD precursors. Wild type FMDVs expressing 3 copies of VPg show three precursors of lower mobility than 3CD that may correspond to 3BCD, 3BBCD and 3BBBCD, respectively. Mutant FMDVs expressing one VPg show only one precursor above 3CD that may correspond to 3BCD. C, Western blot analysis of samples described in A. Proteins were visualised with a specific polyclonal antibody against FMDV 3D [62]. Molecular size markers were run in parallel and their position is indicated on the left. The positions of viral proteins P3, 3CD, and 3D are indicated [62]. Note that precursor P3 (3ABCD) from the mutant transcripts expressing one VPg displayed a higher mobility than WT P3. A band above 3CD was detected in some lanes (indicated with an asterisk) that may correspond to precursor 3BCD in V19–4 R55W and to precursors 3BCD, 3BBCD and/or 3BBBCD in FMDV WT, with or without R55W in 2C. D, Proportion of viral polymerase 3D (as percentage of the value obtained in the electroporation with 8 μg of FMDV WT transcript), measured by densitometry of electropherograms as that shown in A. Values are the average of triplicate protein analyses of independent labelling experiments, and standard deviations are given. WT (0.25x) indicates transfections with 2 μg of WT. The assignment of viral proteins was based on reactivity with specific monoclonal antibodies [39,62,66]. Procedures are described in Materials and Methods. doi:10.1371/journal.pone.0010735.g007

Table 2. Mutations in populations V19–4A and V19–4AB after 27 passages in BHK–21 cells.

| Genomic region | Mutation | Amino acid substitution | V19–4 population |
|----------------|----------|-------------------------|------------------|
| VP1            | A1244G   | D69G                    | V19–4A           |
|                | C3650C/U | T148M                   | V19–4A           |
| VP1            | C3653A/C | T149K                   | V19–4A           |
| 2C             | C4507U   | R55W                    | V19–4A           |
|                | U4597G   | I85V                    | V19–4B           |
| 3A             | A5573G   | E92G                    | V19–4B           |
| VPg–coding region | G5779A | E8K                     | V19–4A; V19–4B |
| 3D             | U7341C/U | —                       | V19–4B           |

*The consensus sequence of the entire viral genome was determined for FMDV populations V19–4A and V19–4B after 27 passages in cell culture.

**FMDV genomic region analysed [15].**

Mutations and deduced amino acid substitutions are relative to the sequence of the parental clone FMDV WT (pMT28, described in Materials and Methods); residue numbering is according to [49]. Amino acid residues (single-letter code) are numbered individually for each protein from the N– to the C–terminus. Two residues separated by a bar indicate a mixture of two nucleotides in the population, according to the sequence chromatogram pattern. Procedures for nucleotide sequencing and identification of FMDV genomic regions are described in Materials and Methods.

*Populations in which the substitutions indicated in * were found.

*Substitution E8K (G5779A) was found repeated in population V19–4 at passage 27 in series A and B (underlined).

doi:10.1371/journal.pone.0010735.t002
in the number of VPg copies or their amino acid sequence could
turb these 2C–3AB interactions. In addition to the replace-
ments in 2C and 3B, substitutions in 3A were also found in
populations and biological clones that regained the plaque–
forming phenotype upon passage in BHK–21 cells, supporting
that recovery of this phenotype can be mediated by any of a
number of readjustments in the interaction among several non–
structural proteins (Tables 1 and 2).

The present investigation has established non–structural
proteins 2C, 3A and VPg as key determinants for modulating
cytopathology in cell culture. For several picornaviruses it has
been shown that replacements either in 2C or 3A can be
associated with modifications of virulence, cell tropism or host
range [40,53–57]. Altogether, these data highlight the role of
non–structural proteins in the adaptability to changing environ-
ments during picornavirus infections, with clear implications for
viral pathogenesis.

Materials and Methods

Plasmids, cells and viruses

pMT28 is a pGEM–1 plasmid (Promega) that contains the
complete cDNA genomic sequence of FMDV serotype C [FMDV
WT: C-S8c1 as described in [41,58,59]]. To produce infectious
transcripts, pMT28 was linearised with Nde
I (NEB), and
transcribed with SP6 polymerase (Promega), following described
procedures [60,61]. Mutant plasmids encoding only one VPg copy
were constructed by mutagenic PCR with primers harboring the
deletion (overlapping upstream and downstream sequences
of the region to be deleted). Two amplifications were made and
then the DNA products were shuffled to introduce the deletion.
The first amplification was performed with a forward primer
spanning residues 3988 to 4009 and a mutagenic reverse primer
spanning either residues 5980–5971 and 5826–5804 (to obtain the
deletion of 5827 to 5970, mutant V1), or residues 5910–5899 and

Figure 8. Effect of replacement E8K in VPg on the specific infectivity of V19–4 (R55W). A, Plaque assay with cells transfected with RNA
transcripts of WT or the indicated mutant constructs. At 2 hours post–transfection, the cell culture supernatants were removed and the cells were
covered with semisolid agar. Plaques were visualized either at 48 or 72 hours post–transfection. Note that substitutions R55W in 2C and E8K in VPg
enhanced the plaque-forming capacity of V19–4. B, Specific infectivity (calculated as the ratio of the number of PFUs obtained to the ng of RNA used
in the electroporation) for WT and the indicated V19–4 mutants. C, Total and extracellular FMDV RNAs measured at 6 hours after electroporation of
BHK–21 cells with WT and the indicated V19–4 mutant RNAs. D, Amount of viral polymerase (3D) determined by metabolic labelling after
electroporation of BHK–21 cells with the indicated RNAs, and densitometry of the relevant protein band. The results are expressed as percentage of
the amount measured following electroporation with WT RNA, which is taken as 100%. Values in B, C, D are the average of 3 determinations; standard
deviations are given. Procedures are described in Materials and Methods.
doi:10.1371/journal.pone.0010735.g008
The plasmid was digested with NsiI (position 5412) and G6393A (antisense) (position 5412), and NsiI (antisense) was introduced into pMT28, previously digested with NcoI and PmlI, to generate pMT28R55W. The mutagenised PCR products were inserted into pMT28R55W (sense orientation), or 4924 to 4944 (sense) and 5026 to 5047 (antisense) (position 5412). RT-PCR amplification of RNA from population V19–4 at passage 27, that encodes 2C with R55W, was performed with primers spanning residues 4189 to 4211 (sense) and 5432 to 5392 (antisense). The amplification product was introduced into plasmid pMT30 by recombination using the In-Fusion Dry and Damp Mix kit (Clontech).

Table 3. Relative amounts of mutant FMDV RNA released from cells a.

| Electroporated FMDV transcript b | Viral RNA released (%) c | Calculated number of infectious particles released per cell d | Plaque-forming capacity e |
|----------------------------------|--------------------------|-------------------------------------------------------------|---------------------------|
| WT                              | 100±4.8                  | 34±3.0                                                      | Yes                       |
| WT R55W                         | 356±65                   | 121                                                         | Yes                       |
| V19–4                           | 7±1                      | 2                                                           | No                        |
| V19–4 R55W                      | 14±10                    | 5                                                           | At 72 hpt                 |
| V15–9                           | 5±1                      | 2                                                           | No                        |
| V15–9 R55W                      | 32±15                    | 11                                                          | Yes                       |
| V3                              | 9±5                      | 3                                                           | No                        |
| V3 R55W                         | 79±30                    | 27                                                          | Yes                       |

a105 BHK-21 cells were electroporated with 8 μg of FMDV RNA, and the amount of extracellular FMDV RNA at 6 hours post-electroporation was quantitated as detailed in Materials and Methods.

bMutant FMDVs analysed. Their construction is described in Materials and Methods, and depicted in Figure 1; R55W indicates the presence of replacement R55W in 2C.

cViral RNA released per cell for the indicated transcripts. Values are expressed as the percentage of the amount of RNA released per cell in the transfections with FMDV WT. Each value is the average of at least three determinations; standard deviations are given. Relative viral RNA released per cell in mutant FMDVs defective in plaque-forming capacity is below 20% of FMDV WT (calculated from data shown in Figure 5).

dCalculated number of infectious particles released per cell for wild type and mutant FMDVs. An average number of 34 PFU are released per cell in infections with FMDV WT (data in Figure 3). The calculation assumes that one FMDV WT infectious particle is equivalent to one PFU, and that the number of infectious particles released by each mutant virus correlates with the viral RNA released.

ePlaque-forming capacity of mutant FMDV transcripts (data in Figure 4). Yes indicates the ability of mutant transcripts to develop plaques in 48 h; No indicates that no plaques were observed at 72 hours post-electroporation. Plaque development with V19–4 R55W was only observed at 72 hours post-electroporation. Procedures for plaque assays of viral transcripts are detailed in Materials and Methods.

doi:10.1371/journal.pone.0010735.t003

Transfection of viral RNA transcripts into BHK-21 cells
Viral replication of each mutant FMDV was analysed by transfection of the corresponding transcript into BHK-21 cells. For this purpose we used both lipofection and electroporation methods. Lipofection was used to obtain mutant viral samples that were then passaged on BHK-21 cell monolayers, and also in plaque assays of viral transcripts. Electroporation was used to detect intracellular FMDV protein synthesis, and in the quantification of intracellular FMDV RNA synthesis relative to viral RNA release. Lipofection and electroporation were carried out as previously described [41,62].

Extraction of RNA, cDNA synthesis, PCR amplification, and nucleotide sequencing
RNA was extracted from the supernatants of infected cells by treatment with Trizol (Invitrogen) as previously described [63]. Reverse transcription (RT) was carried out using avian myeloblastosis virus reverse transcriptase (Promega) or Transcriptase reverse transcriptase (Roche), and PCR amplification was performed using EHF DNA polymerase (Roche) as specified by the manufacturer. PCR amplifications to obtain mutant infectious clones were carried out using Pfu Turbo DNA polymerase (Stratagen) because of its high copying fidelity [64]. Nucleotide sequencing was carried out as described [61].

Plaque assays of viral samples
Plaque assays were performed as previously described [65]. Serial dilutions of viral samples were applied to confluent BHK-21 cell monolayers and incubated for 1 h at 37°C. Then, supernatants were removed and semisolid agar medium was added. Plaque development was permitted for 48 h post-infection.

Plaque assay of directly transfected infectious RNA transcripts
Serial dilutions of in vitro transcribed infectious RNA (10, 1 and 0.1 ng) were mixed with lipofectin (Invitrogen) as indicated by the manufacturer. The mixture was added to a monolayer of 2×105 BHK-21 cells and incubated for 2 h at 37°C. Then, the medium was removed, the cell monolayer was washed with DMEM and semisolid agar medium was added. Plaque development was permitted for either 48 or 72 h.

Quantification of viral RNA in cell culture samples
Quantitative real-time RT–PCR was carried out using the Light Cycler RNA Master SYBR Green I kit (Roche), according to the instructions of the manufacturer. Oligonucleotides spanning residues 3175 to 3194 (sense orientation) and 3518 to 3496 (antisense orientation), or 4924 to 4944 (sense) and 5026 to 5047 (antisense) were used in the amplification. Quantification was
relative to a standard curve obtained with known amounts of FMDV RNA, synthesised by in vitro transcription of the infectious plasmid pMT28 [41]. For the quantification of extracellular FMDV RNA, the supernatants were collected, freed from detached cells by centrifugation, and extracted with Trizol (Invitrogen).

Metabolic labelling of viral proteins
To detect viral protein synthesis in transfected cells, 2 to 8 μg of viral transcript were electroporated into 2 × 10^6 BHK-21 cells. Electroporated cells were incubated for 3–4 hours in culture medium (DMEM, 1% FCS). Then, the medium was removed and cells were incubated for 1 h at 37°C in DMEM without Met and Cys, but supplemented with [35S] Met-Cys (Perkin-Elmer) (400 mCi/mmol). After metabolic labelling, cells were collected in 0.1 ml of sample buffer [160 mM Tris–HCl pH 6.8; 2% SDS; 1% glycerol; 0.1 M DTT; 0.033% bromophenol-blue]. The samples were heated at 90°C for 5 min and aliquots were subjected to SDS-PAGE (15% acrylamide).

Western blot assays
Proteins were transferred to a 0.45 μm pore size nitrocellulose membrane (BioRad). Western blots were developed with the following antibodies at a dilution of 1:2,000: mouse monoclonal anti-2C (1C8) and anti–3C (2D2) (a gift from E. Brocchi, Istituto Zooprofilattico Sperimentale della Lombardia e dell’Emilia Romagna, Brescia, Italy) and rabbit polyclonal anti-3D. Goat anti-rabbit IgG antibody coupled to peroxidase and goat anti–mouse IgG antibody coupled to peroxidase (Pierce) were used at 1:10,000 dilutions. Each sample was analysed by Western blot to identify virus–specific proteins, following previously described procedures [62].

Acknowledgments
We are indebted to E. Brocchi for the generous supply of MAbs, and to A. I. de Ávila and E. García–Cueto for expert technical assistance.

Author Contributions
Conceived and designed the experiments: AA CE ED. Performed the experiments: AA CP. Analyzed the data: AA CP CE ED. Contributed reagents/materials/analysis tools: AA CP CE ED. Wrote the paper: AA ED.

References
1. Lewin B (2007) Genes. Sudbury. Massachusetts: Jones & Bartlett Publishers Inc.
2. Ball LA (2007) Virus replication strategies. In: Knipe DM, Howley PM, eds. Fields Virology, 5th ed Philadelphia: LWW. pp 119–140.
3. Ferrer-Orrza C, Arias A, Agudo R, Perez-Luque R, Ecarraez C, et al. (2006) The structure of a protein primer–polymerase complex in the initiation of genome replication. EMBO J 25: 880–888.
4. Kamekura S, Berman AJ, Wang J, Lazar0 JM, de Vega M, et al. (2006) The phi29 DNA polymerase–protein–primer structure suggests a model for the initiation to elongation transition. EMBO J 25: 1335–1343.
5. Salas M (1991) Protein–priming of DNA replication. Annu Rev Biochem 60: 39–71.
6. Paull AV (2002) Possible unifying mechanism of picornavirus genome replication; Semler BL, ed, Wimmer E. Washington DC: ASM Press. pp 237–246.
7. Paul AV, van Boom JH, Filippe D, Wimmer E (1998) Protein–primed RNA synthesis by purified poliovirus RNA polymerase. Nature 393: 280–284.
8. Fors S, Schaller H (1982) A tandem repeat gene in a picornavirus. Nucleic Acids Res 10: 6441–6450.
9. King AM, Sangar DV, Brown TJ, Brown F (1980) Heterogeneity of the genome–specific RNA molecules of poliovirus. J Virol 34: 627–634.
10. Nayak A, Goddelflow IG, Belsham GJ (2005) Factors required for the Uridylylation of the foot–and–mouth disease virus 3B1, 3B2, and 3B3 peptides by the RNA–dependent RNA polymerase (3Dpol) in vitro. J Virol 79: 7698–7706.
11. Fulk MM, Sobrino F, Beck E (1992) VPg gene amplification correlates with infective particle formation in foot–and–mouth disease virus. J Virol 66: 2251–2260.
12. Pacheco JM, Henry TM, O’Donnell VK, Gregory JB, Mason PW (2003) Role of nonstructural proteins 3A and 3B in host range and pathogenicity of foot–and–mouth disease virus. J Virol 77: 13017–13027.
13. Cao X, Kuhn RJ, Wimmer E (1993) Replication of poliovirus RNA containing two VPg coding sequences leads to a specific deletion event. J Virol 67: 5372–5378.
14. Cao X, Wimmer E (1996) Genetic variation of the poliovirus genome with two VPg coding units. EMBO J 15: 23–33.
15. Ryan MD, Donnelly MLL, Flint M, Cowton VM, Luke G, et al. (2004) Foot–and–mouth disease virus proteins. In: Sobrino F, Domingo E, eds. Foot–and–mouth disease: current perspectives. Wymondham, UK: Horizon Bioscience. pp 53–76.
16. Nayak A, Goddelflow IG, Woolaway KE, Birley J, Curry S, et al. (2006) Role of RNA structure and RNA binding activity of foot–and–mouth disease virus 3C protein in VPg uridylylation and virus replication. J Virol 80: 9863–9875.
17. Marcott EL, Wass AB, Gohara DW, Pathak HB, Arnold JJ, et al. (2007) Crystal structure of poliovirus 3CD protein: virally encoded protease and precursor to the RNA–dependent RNA polymerase, J Virol 81: 3583–3596.
18. Paul AV, Peters J, Mugavero J, Yin J, van Boom JH, et al. (2003) Biochemical and genetic studies of the VPg uridylylation reaction catalyzed by the RNA polymerase of poliovirus. J Virol 77: 891–904.
38. Verdaguer N, Fina I, Domingo E, Mateu MG (1997) Efficient neutralization of foot-and-mouth disease virus by monovalent antibody binding. J Virol 71: 9813–9816.
39. Perales C, Agudo R, Domingo E (2009) Counteracting quasispecies adaptability: extinction of a ribavirin-resistant virus mutant by an alternative mutagenic treatment. PLoS Pathog 5: e5554.
40. Herrera M, Garcia-Arriaza J, Pariente N, Escarmis C, Domingo E (2007) Molecular basis for a lack of correlation between viral fitness and cell killing capacity. PLoS Pathog 3: e55.
41. Garcia-Arriaza J, Manrubia SC, Toja M, Domingo E, Escarmis C (2004) Evolutionary transition toward defective RNAs that are infectious by complementation. J Virol 78: 11678–11685.
42. Carrillo C, Tulman ER, Delhon G, Li Z, Carreno A, et al. (2005) Comparative genomics of foot-and-mouth disease virus. J Virol 79: 6487–6504.
43. Yin J, Paul AV, Wimmer E, Rieder E (2003) Functional dissection of a poliovirus cis-acting replication element [PV-cre(2C)]: analysis of single- and dual-cre viral genomes and proteins that bind specifically to PV-cre RNA. J Virol 77: 5152–5166.
44. Domingo E, Escarmis C, Menéndez-Arias L, Perales C, Herrera M, et al. (2008) Viral quasispecies: dynamics, interactions and pathogenesis. In: Domingo E, Parrish C, Holland J.J., eds. Origin and Evolution of Viruses, 2nd ed Oxford, UK: Elsevier. pp 87–118.
45. Gruhman MJ, Moraes MP, Diaz-San Segundo F, Pena L, de los Santos T (2008) Evading the host immune response: how foot-and-mouth disease virus has become an effective pathogen. FEMS Immunol Med Microbiol 53: 8–17.
46. Sierra S, Davila M, Lowenstein PR, Domingo E (2006) Response of foot-and-mouth disease virus to increased mutagenesis: influence of viral load and fitness in loss of infectivity. J Virol 74: 8316–8323.
47. Belsham GJ, Normann P (2008) Dynamics of picornavirus RNA replication within infected cells. J Gen Virol 89: 485–493.
48. Pariente N, Arakinski A, Domingo E (2003) Mutagenesis versus inhibition in the efficiency of extinction of foot-and-mouth disease virus. J Virol 77: 7131–7138.
49. Baranowski E, Sevilla N, Verdaguer N, Ruiz-Jarabo CM, Beck E, et al. (1998) Multiple virulence determinants of foot-and-mouth disease virus in cell culture. J Virol 72: 6362–6372.
50. Martinez-Salas E, Saiz JC, Davila M, Belsham GJ, Domingo E (1993) A single nucleotide substitution in the internal ribosome entry site of foot-and-mouth disease virus leads to enhanced cap-independent translation in vivo. J Virol 67: 3748–3755.
51. Escarmis C, Perales C, Domingo E (2009) Biological effect of Muller’s Ratchet: distant capid site can affect picornavirus protein processing. J Virol 83: 6748–6756.
52. Ferrer-Orra C, Arias A, Escarmis C, Verdaguer N (2006) A comparison of viral RNA-dependent RNA polymerases. Curr Opin Struct Biol 16: 27–34.
53. Wang YF, Zhou CT, Lei HY, Liu CC, Wang SM, et al. (2004) A mouse-adapted enterovirus 71 strain causes neurological disease in mice after oral infection. J Virol 78: 7916–7924.
54. Harris JR, Racanello VR (2005) Changes in rhinovirus protein 2C allow efficient replication in mouse cells. J Virol 77: 4773–4780.
55. Harris JR, Racanello VR (2005) Amino acid changes in proteins 2B and 3A mediate rhinovirus type 39 growth in mouse cells. J Virol 79: 5363–5373.
56. Sanz-Ramos M, Díaz-San Segundo F, Escarmis C, Domingo E, Sevilla N (2008) Hidden virulence determinants in a viral quasispecies in vivo. J Virol 82: 10465–10476.
57. Núñez JJ, Baranowski E, Molina N, Ruiz-Jarabo CM, Sanchez C, et al. (2001) A single amino acid substitution in nonstructural protein 3A can mediate adaptation of foot-and-mouth disease virus to the guinea pig. J Virol 75: 3977–3983.
58. Toja M, Escarmis C, Domingo E (1999) Genomic nucleotide sequence of a foot-and-mouth disease virus clone and its persistent derivatives. Implications for the evolution of viral quasispecies during a persistent infection. Virus Res 64: 161–171.
59. Escarmis C, Davila M, Charpentier N, Bracho A, Moya A, et al. (1996) Genetic lesions associated with Muller’s ratchet in an RNA virus. J Mol Biol 255: 255–267.
60. Arias A, Agudo R, Ferrer-Orra C, Perez-Laque R, Airaksinen A, et al. (2005) Mutant viral polymerase in the transition of virus to error catastrophe identifies a critical site for RNA binding. J Mol Biol 353: 1021–1032.
61. Sierra M, Airaksinen A, Gonzalez-Lopez C, Agudo R, Arias A, et al. (2007) Foot-and-mouth disease virus mutant with decreased sensitivity to ribavirin: implications for error catastrophe. J Virol 81: 2012–2024.
62. Perales C, Mateo R, Mateu MG, Domingo E (2007) Insights into RNA virus mutant spectrum and lethal mutagenesis events: replicative interference and complementation by multiple point mutants. J Mol Biol 369: 983–1000.
63. Arias A, Ruiz-Jarabo CM, Escarmis C, Domingo E (2004) Fitness increase of an RNA virus mutant spectrum and lethal mutagenesis events: replicative interference and complementation by multiple point mutants. J Mol Biol 369: 983–1000.
64. Arias A, Ruiz-Jarabo CM, Escarmis C, Domingo E (2004) Fitness increase of an RNA virus mutant spectrum and lethal mutagenesis events: replicative interference and complementation by multiple point mutants. J Mol Biol 369: 983–1000.
65. Arias A, Lazaro E, Escarmis C, Domingo E (2001) Molecular intermediates of fitness gain of an RNA virus: characterization of a mutant spectrum by biological and molecular cloning. J Gen Virol 82: 1049–1060.
66. Perales C, Agudo R, Tejero H, Manrubia SC, Domingo E (2009) Potential benefits of sequential inhibitor-mutagen treatments of RNA virus infections. PLoS Pathog 5: e1000638.